Clinical Outcome of Low-risk Differentiated Thyroid Cancer Patients after Radioiodine Remnant Ablation and Recombinant Human Thyroid-stimulating Hormone Preparation

Clinical Oncology

Volumn 24, Issue 3, 2012, Pages 162-168

  Vianello, F ^a   Mazzarotto, R ^b   Mian, C ^c   Lora, O ^a   Saladini, G ^a   Servodio, O ^a   Basso, M ^a   Pennelli, G ^c   Pelizzo, M R ^c   Sotti, G ^a  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Radioactive iodine; Remnant ablation; RhTSH; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN; THYROGLOBULIN; THYROGLOBULIN ANTIBODY; THYROTROPIN; THYROXINE;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURGERY; CLINICAL EFFECTIVENESS; DIFFERENTIATED THYROID CANCER; FEMALE; FOLLOW UP; FREE THYROXINE INDEX; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; THYROGLOBULIN BLOOD LEVEL; THYROID FUNCTION TEST; THYROIDECTOMY; THYROTROPIN BLOOD LEVEL; TUMOR ABLATION;

ADENOCARCINOMA, FOLLICULAR; ADENOCARCINOMA, PAPILLARY; ADULT; AGED; AGED, 80 AND OVER; CELL DIFFERENTIATION; COMBINED MODALITY THERAPY; CROSS-SECTIONAL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; THYROID NEOPLASMS; THYROIDECTOMY; THYROTROPIN; TREATMENT OUTCOME; WHOLE BODY IMAGING;

EID: 84857912523     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2011.02.011     Document Type: Article

References (32)

1. Mazzaferri E.L. Editorial: a randomized trial of remnant ablation in search of an impossible dream?. J Clin Endocrinol Metab 2004, 89(8):3662-3664.
2. Schlumberger M., Pacini F., Wiersinga W.M., et al. Follow-up and management of differentiated thyroid carcinoma: a European perspective in clinical practice. Eur J Endocrinol 2004, 151:539-548.
3. Cooper D.S., Doherty G.M., Haugen B.R., et al. The American thyroid association guidelines taskforce. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2006, 16:109-142.
4. Pacini F., Schlumberger M., Dralle H., Elisei R., Smit J.W., Wiersinga W. European thyroid cancer taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006, 154:787-803.
5. Thyroid Carcinoma Task Force AACE/AAES medical/surgical guidelines for clinical practice: management of thyroid carcinoma. American association of clinical endocrinologists. Endocr Pract 2001, 7:202-220.
6. British Thyroid Association Guidelines for the management of differentiated thyroid cancer in adults 2002, Royal College of Physicians, London.
7. Cooper D.S., Doherty G.M., Haugen B.R., et al. Revised American thyroid association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009, 19(11):1167-1214.
8. Wartofsky L., Sherman S.I., Gopal J., Schlumberger M., Hay I.D. Therapeutic controversy. The use of radioactive iodine in patients with papillary and follicular thyroid cancer. J Clin Endocrinol Metab 1998, 83:4195-4203.
9. Mazzarerri E.L., Kloos R.T. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab 2001, 86(4):1447-1463.
10. Mazzaferri E.L., Young R.L., Oertel J.E., Kammerer W.T., Page C.P. Papillary thyroid carcinoma: the impact of therapy in 576 patients. Medicine 1977, 56:171-196.
11. Grebe S.K.G., Hay I.D. Follicular cell-derived thyroid carcinomas. Endocrine neoplasms 1997, 91-140. Kluwer Academy Publishers. A. Arnold (Ed.).
12. Schlumberger M., Hay I.D. Use of radioactive iodine in patients with papillary and follicular thyroid cancer: towards a selective approach. J Clin Endocrinol Metab 1998, 8(12):4201-4203.
13. Simpson W.J., Panzarella T., Carruthers J.S., Gospodarowicz M.K., Sutcliffe S.B. Papillary and follicular thyroid cancer: impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988, 14:1063-1075.
14. Luster M., Lippi F., Jarzab B., et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 2005, 12:49-64.
15. Robbins R.J., Larson S.M., Sinha N., et al. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 2002, 43:1482-1488.
16. Pacini F., Ladenson P.W., Schlumberger M., et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 2006, 91:926-932.
17. Barbaro D., Boni G., Meucci G., et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in l-thyroxine in the outcome of ablation. J Clin Endocrinol Metab 2003, 88:4110-4115.
18. 131I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 2002, 87:4063-4068.
19. Pilli T., Brianzoni E., Capoccetti F., et al. A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 2007, 92(9):3542-3546.
20. Chianelli M., Todino V., Gaziano F.M., et al. Low-activity (2.0 GBq; 54 mCi) radioiodine post-surgical remnant ablation in thyroid cancer: comparison between hormone withdrawal and use of rhTSH in low-risk patients. Eur J Endocrinol 2009, 160:431-436.
21. Tuttle R.M., Brokhin M., Gal O., et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 2008, 49(5):764-770.
22. Elisei R., Schlumberger M., Driedger A., et al. Follow-up of low-risk differentiated thyroid cancer patient who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 2009, 94(11):4171-4179.
23. Torres M.S., Ramirez L., Simikin P.H., Braverman L.E., Emerson C.H. Effect of various doses of recombinant human thyrotropin on the thyroid radioactive iodine uptake and serum levels of thyroid hormones and thyroglobulin in normal subjects. J Clin Endocrinol Metab 2001, 86:1660-1664.
24. Pacini F., Molinaro E., Lippi F., et al. Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 2001, 86(12):5686-5690.
25. Hackshaw A., Harmer C., Mallick U., Haq M., Franklyn J.A. Review: 131I activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab 2007, 92(1):28-38.
26. Mazzaferri E.L., Jhiang S.M. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994, 97:418-428.
27. Pacini F., Agate L., Elisei R., et al. Outcome of differentiated thyroid cancer with detectable serum Tg and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. J Clin Endocrinol Metab 2001, 86(9):4092-4097.
28. Spencer C.A. Challenges of serum thyroglobulin (Tg) measurement in the presence of Tg autoantibodies. J Clin Endocrinol Metab 2004, 89(8):3702-3704.
29. Sawka A.M., Thephamongkhol K., Brouwers M., Thabane L., Browman G., Gerstein H.C. A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. J Clin Endocrinol Metab 2004, 89(8):3668-3676.
30. Clarke S.E.M. Radioiodine therapy in differentiated thyroid cancer: a nuclear medicine perspective. Clin Oncol 2010, 22(6):430-437.
31. Kloos R.T., Mazzaferri E.L. A single recombinant human thyrotropin-stimulated serum thyroglobulin measurement predicts differentiated thyroid carcinoma metastases three to five years later. J Clin Endocrinol Metab 2005, 86:1660-1664.
32. Rees G.J.G. Radioiodine ablation for differentiated thyroid cancer - none, one dose or two?. Clin Oncol 2010, 22(2):131-135.